Quote | Super Quote
Super Quote   |   Detail Quote   |   Interactive Chart   |   Transaction   |   Related News   |   Related Securities   |   Company Information   |   Dividend Records   |   Short Sell
00867 CMS
RTNominal up7.060 +0.010 (+0.142%)
Others

20/11/2017 17:53

[I-bank focus]UBS lifts CMS (00867) to HK$17.7; "buy"

[ET Net News Agency, 20 November 2017] UBS Global Research lifted its target price for
China Medical System (CMS)(00867) to HK$17.7 from HK$16.1, and maintained its "buy"
rating.
The research house said 3Q hospital sales data again confirms CMS's strong academic
promotion capability. Growth of Plendil continues to improve, and volume of XHS picks up
rapidly in September, the first month after the new NDRL implementation, a surprise, UBS
noted.
UBS lifted its EPS forecasts by 2% to reflect the likely better than expected sales
trend. (KL)

Back to Others

Remark: Real time quote last updated: 18/04/2024 17:59
  Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2024 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.